I agree with many of the points about checklists and pre-review meetings, but another helpful step is making sure the story of the design is clear before the meeting. Instead of just compiling documen...

One idea that stood out to me in this discussion is that the decision to return to a previous phase is less about the amount of error and more about the type of issue being discovered. Sometimes early...

One angle I find interesting is how collaborations like BoneFix and FactoSet aren’t just about leveraging expertise or cutting costs, they also distribute regulatory and technical risks. In biomedical...

I agree with Dev Doshi and Ehab B. that avoidance isn’t always the best strategy, especially for life-sustaining devices where eliminating risk could mean removing essential features. I’d add that avo...

I really appreciate all the insights shared here, especially the idea of running parallel validation to minimize production disruptions. Building on Dev Doshi’s point about regional divergence, one th...

I really like the point that the DHF isn’t the true deliverable, but rather the evidence of sound decision-making. I don’t think the PM’s role shifts away from task management, but instead, task manag...

One angle I’d add is that in medical device development, credibility with cross-functional teams can matter just as much as credentials on paper. A technical degree may help you earn trust from R&...

I like the ideas about SharePoint and dashboards, but I wonder if the format matters less than when the lessons are captured. If teams wait until the final closeout, a lot of smaller but important ins...

I think aligning business needs and customer satisfaction starts with redefining them as interdependent rather than competing priorities. In medical devices, especially, long-term revenue is directly ...

I think the root issue here isn’t just version control software: it’s process discipline. If a design change request isn’t based on the latest revision, it should be formally rejected before review ev...

I think this situation is less about a design flaw and more about the original business assumption being challenged by real data. If the stent dissolves too quickly to provide long-term vessel support...

I think one aspect that often gets overlooked is how company culture affects the integration of design controls and project management. Even with shared documents and aligned meetings, the DHF can sti...

I think one commonly overlooked part of creating a strong DHF is treating it as an evolving document instead of something put together at the very end of the project. A PM can help by setting clear do...

One additional factor that strongly influences the medical device product life cycle is post-market surveillance and real-world performance data, which can extend or shorten a device’s lifespan after ...

Based on my research, I’d be interested in starting a medical device project focused on a collagen–chitosan hydrogel bandage for treating second-degree burns, since it has strong potential to support ...